Good MorningThe major indices held steady on Monday in what was an otherwise uneventful day of trading. The S&P 500 fell about 0.50% on an intraday basis but reclaimed about half of the loss before the close of the session. The day’s action is a sign of caution and not a little indecision. With so much riding on the economic rebound and COVID cases on the rise, a little caution is more than warranted.
This week could be a volatile one for investors. The market is waiting for the next cue and it could come from Congress at any time. Hopes for a bipartisan COVID relief bill continue to grow despite a lack of commitment from Republican leadership. If passed the bill would send another surge of stimulus through the economy but there is another risk as well. That risk is a government shut-down. A stop-gap effort to keep the government running for a week is probably not enough to get the stimulus deal done. If the aid package falls apart like it did before the market could take a dive.
Featured: Wall Street’s quietly buying these 3 AI infrastructure plays (Ad) 
|
Energy | | Solid-oxide fuel cell systems provider Bloom Energy (NYSE: BE) stock has seen a resurgence from the electric vehicle (EV) momentum. As momentum and money flow frantically shifts from EVs to EV fueling, power sources and materials, shares of former momentum flyers FuelCell Energy, Inc. (NASDAQ: FCEL)... Read the Full Story |
|
From Our Partners | | BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | | Get the name, the ticker, and exactly how to buy it |
|
Finance | | The S&P 500 (NYSEARCA: SPY) is grinding through all-time highs heading into year’s end as the pandemic ravages a third wave in a race for FDA COVID-19 vaccine approvals and distribution. While pundits argue the markets are disconnected with reality, this is the seasonal time of year where ... Read the Full Story |
|
Medical | |
Every situation produces a certain number of winners. Even disastrous situations like the coronavirus pandemic produced a few winners, especially for segments with “from-home” somewhere in their concepts. “Work-from-home,” “exercise-from-home,” and “shop-f... Read the Full Story |
|
From Our Partners | | See the Signals Most Traders Miss
We monitor subtle shifts in order flow, volume patterns, and early trend behavior.
Stock News Trends highlights moves long before they hit mainstream screens. | | Join Free — Start Tracking Early Market Data |
|
Retail/Wholesale | | A Changing Landscape For Mall-Based RetailersThe mall-based brick&mortar retail industry has been on the rocks for years. The pandemic didn’t cause this problem it only accelerated a shift to digital and non-mall retailers that was already in place. What this means for many mall-based reta... Read the Full Story |
|
Consumer Discretionary | | Record Demand Drives Profit For Smith & Wesson Brands
Smith & Wesson Brands (NASDAQ:SWBI) reported a fantastic fiscal 2nd quarter and it looks like these gains could stick. Based on the number of federal background checks and the number of 1st-time buyers the stage is set for solid gains ac... Read the Full Story |
|
From Our Partners | | With OpenAI and Anthropic moving closer to the IPO spotlight, AI excitement could spill into several public-market sectors this summer - and most investors may chase the obvious names too late.
A free report identifies 7 stocks positioned around themes that could matter most this summer: AI infrastructure, energy demand, travel, entertainment, home improvement, and more. Built for a market where leadership may rotate quickly. | | Download 7 Best Stocks to Own in Summer 2026 for free |
|
Technology | | As if they hadn’t been performing well enough this year already, shares of mobile payment company Square (NYSE: SQ) have been on a fresh rally to all-time highs since reporting Q3 earnings a month ago. They had already rode the wave of this past summer’s hype around all things tech and w... Read the Full Story |
|
Retail/Wholesale | | For some companies, just about everything has broken right since the onset of the pandemic. Chewy (NYSE: CHWY), an online retailer of pet food and other pet-related products, is one of those companies:
E-commerce has boomed this year.
The remote work boom has resulted in people moving from city ... Read the Full Story |
|
Retail/Wholesale | | Tilly’s Smashes The Consensus, Shares Fall 15%
Tilly’s Inc (NYSE:TLYS) is another mall-based retailer outperforming its expectations. The company reported 3Q earnings this week and smashed through the consensus producing not only sequential growth but positive earnings for the 2nd time ... Read the Full Story |
|
Medical | |
When you consider the fact that we’ve been dealing with the largest global health crisis in recent memory, it makes a lot of sense to explore some of the best healthcare stocks heading into 2021. Hopefully, we will be able to put the pandemic behind us next year and return to normalcy, but t... Read the Full Story |
|
Consumer Discretionary | |
Amidst a record IPO market, investors continue to add shares of new companies that have the potential to become huge winners in the coming years. While trading stocks that have recently gone public can be a volatile endeavor, that hasn’t stopped the money pouring into new companies with uniq... Read the Full Story |
|
The Early Bird Stock Of The Day Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
